Media releases
- April
- 25-Apr-2013 Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria »
- 24-Apr-2013 Novartis discloses compensation for new Chairman and Chairman ad-interim »
- 24-Apr-2013 Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth »
- 23-Apr-2013 Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients »
- 19-Apr-2013 Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients »
- 01-Apr-2013 Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India »
- March
- 26-Mar-2013 Novartis confirms growing Gilenya® clinical and real-world experience as number of patients treated increases to over 63,000 »
- 21-Mar-2013 New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies »
- 18-Mar-2013 Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole »
- 15-Mar-2013 Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer »
- 13-Mar-2013 Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis »
- 01-Mar-2013 Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments »
- February
- 28-Feb-2013 Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa »
- 24-Feb-2013 Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1] »
- 22-Feb-2013 Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period »
- 19-Feb-2013 Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders »
- 15-Feb-2013 Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients »
- January
- 23-Jan-2013 Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia »
- 23-Jan-2013 Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013 »
- 22-Jan-2013 Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe »
- 18-Jan-2013 Novartis receives positive CHMP opinion for Ilaris® to treat patients whose acute gouty arthritis cannot be managed with standard of care »
- 18-Jan-2013 Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole »
- 17-Jan-2013 Novartis makes progress in the fight to eliminate leprosy worldwide »
- 14-Jan-2013 Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero® to help provide broad protection to infants against MenB »
- 11-Jan-2013 Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
